Danielle M. Lauzon

Danielle M. Lauzon

PartnerBoston Business Law Leader
Danielle M. Lauzon
Boston
+1 617 570 1955

Danielle Lauzon is a partner in Goodwin’s Technology and Life Sciences groups, and leader of the firm’s Business Law Department in Boston. Ms. Lauzon represents issuers in connection with the public offering and private placement of equity securities, and has represented companies as well as venture capital and private equity firms in numerous venture capital financings and recapitalizations. From 2007 through 2012, Ms. Lauzon was recognized as Massachusetts Super Lawyer “Rising Star” for her work representing private and public companies on general corporate and securities law and mergers and acquisitions.

Ms. Lauzon acts as co-chair of Goodwin’s PropSci practice which is focused on supporting the intersection of real estate and life sciences. Through our industry and practice area connectivity, and leveraging our existing reputation as leaders in the real estate and life sciences spaces, Goodwin provides clients integrated and innovative services that adapt along with their needs.

Ms. Lauzon currently serves on Goodwin’s Partnership Committee.

Experience

Ms. Lauzon’s representation of start-up and later stage companies spans the entire corporate life cycle, including formation matters, general corporate representation and counseling, venture capital financings, public offerings and mergers and acquisitions. Her clients are in the life sciences and healthcare information technology services industries. Her recent representations include:

  • Bellus Health in its $200 million public offering
  • Adicet Bio in its $87.5 million public offering
  • Blueprint Medicines in its acquisition of Lengo Therapeutics
  • Aura Biosciences in its $75.6 million initial public offering
  • .406 Ventures in its investment in Diana Health
  • Laronde in its $440 million Series B financing
  • Aerpio Pharmaceuticals in its reverse merger with Aadi Biosciences and concurrent private placement
  • Aura Biosciences in its $80 million financing
  • ElevateBio in its $525 million Series C financing
  • Adicet Bio in its $130 million public offering and concurrent $15 million private placement
  • Cullinan Oncology in its $249.9 million initial public offering
  • Cullinan Oncology in its $131.2 million Series C financing
  • BELLUS Health in its $40 million public offering
  • iTeos Therapeutics in its $201.1 million initial public offering
  • AlloVir, Inc. in its $317.7 million initial public offering
  • Unum Therapeutics in its $104.4 million private placement of common stock
  • iTeos Therapeutics in its $125.3 million Series B financing
  • ElevateBio in its $170 million Series B financing
  • Blueprint Medicines Corporation in its $325 million follow-on offering
  • Outcomes4Me in its Series Seed and Series A preferred stock financings
  • Unum Therapeutics in its acquisition of KIQ and concurrent private placement
  • Zafgen in its definitive merger agreement with Chondrial Therapeutics
  • resTORbio, Inc. in its reverse merger with Adicet Bio
  • Semma Therapeutics in its $950 million sale to Vertex
  • Onyx Pharmaceuticals in its $10.4 billion sale to Amgen
  • AMRI in its $1.7 billion (enterprise value) sale to affiliates of The Carlyle Group and GTCR LLC
  • AMRI in its $358 million acquisition of Euticals and $174 million acquisition of Gadea Pharmaceutical Group
  • Blueprint Medicines in its $345 million, $230 million and $125 million follow-on offerings
  • Zafgen in its $60 million underwritten public offering
  • resTORbio, Inc. in its $97.8 million initial public offering
  • Unum Therapeutics in its $69.2 million initial public offering and $5 million concurrent private placement
  • ProQR Therapeutics in its $75 million underwritten public offering
  • ProQR Therapeutics in its $20 million underwritten public offering and concurrent registered direct offering
  • Aerpio Pharmaceuticals in its $40 million underwritten public offering and uplisting to Nasdaq
  • Aerpio Pharmaceuticals in its $40 million reverse merger and private placement
  • Aerpio Pharmaceuticals in its $75 million at-the-market program with Cantor Fitzgerald & Co.
  • Allurion Technologies in its $27 million Series C financing
  • Koneksa Health in its $16 million Series B financing
  • Omega Funds in its investments in Amunix Pharmaceuticals, Endeavor BioMedicines and Vanqua Bio
  • .406 Ventures in its investments in Iora Health, Heartbeat Health, Wellist, and Virtudent
  • Flare Capital in its investments in Eden Health
  • Alector LLC in its Series A, Series B, Series C, and Series D financings
  • Promedior, Inc. in its strategic agreement with Bristol-Myers Squibb
  • Unum Therapeutics in its $65 million Series B financing
  • ProQR Therapeutics N.V. in its $97.5 million initial public offering
  • Conformis in its $20 million follow-on offering with Cowen and Canaccord Genuity
  • Conformis in its $50 million offering of stock with Canaccord Genuity
  • AbleTo, Inc. in its Series A, Series B, Series C, and Series D financings
  • Moderna Therapeutics in the closing of a $110 million financing round
  • Picis Solutions in its sale to Ingenix, a subsidiary of UnitedHealth Group
  • Phase Forward in its sale to Oracle Corporation

Professional Activities

Ms. Lauzon is a member of the Massachusetts and Boston Bar Associations.

Professional Experience

Prior to joining Goodwin, Ms. Lauzon was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston.

Credentials

Education

JD2000

Villanova University School of Law

(magna cum laude, Order of the Coif)

BA1997

University of Michigan

Admissions

Bars

  • Massachusetts

Recognition & Awards

Ms. Lauzon has been recognized by The Legal 500 U.S. for her work in the life science industry, and from 2007 through 2021, she was recognized as a Massachusetts Super Lawyer "Rising Star" by Law & Politics and Boston magazine. In law school, Ms. Lauzon was a member of the Villanova Law Review.